Covid-19 News

  • if it helps.

    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • The data from the doctors lounge


    External Content youtu.be
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • Here you go Jed sanofi press release, I haven't found a connection to Pfizer-BioNTech, or moderns trials. I did post a Pfizer-BioNTech animal study that was suspended after only 56 days. Researchers find that much to short of time.


    Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies


    https://www.sanofi.com/en/medi…/2020/2020-10-15-14-00-00


    Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies


    mRNA-based vaccine candidate MRT5500 induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies

    Two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients

    Phase 1/2 clinical trial anticipated to begin in the fourth quarter of 2020

    PARIS and LEXINGTON, MASS. – October 15, 2020 - Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the preclinical results for MRT5500, a mRNA-based vaccine candidate against SARS-CoV-2, the virus that causes COVID-19 disease.


    Preclinical evaluation of MRT5500, importantly, demonstrated a favorable immune response profile against SARS-CoV-2. These data support the selection of MRT5500 for clinical development. A Phase 1/2 clinical trial is anticipated to begin in the fourth quarter of 2020. Full results are available here. MRT5500 is being developed under a collaboration agreement between Sanofi Pasteur and Translate Bio.


    “To tackle this global pandemic, we must look to both the strong knowledge we have from years of infectious disease expertise and the promise of new, innovative technologies,” said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur. “Today’s presentation of these positive results is another development milestone for providing a safe and effective potential vaccine against SARS-CoV2 and shows how promising this technology is. We are looking forward to working on next steps with our partner Translate Bio to bring this technology to people worldwide.”


    “The rapid development of effective vaccines to address the COVID-19 pandemic continues to be an urgent global public health need and I am encouraged by the progress we’ve made to date with our partner Sanofi Pasteur toward the development of a promising mRNA vaccine candidate,” said Ronald Renaud, Chief Executive Officer at Translate Bio. “The preclinical results we report in this paper demonstrate the ability of MRT5500 to elicit a favorable immune response in both mice and non-human primates. Importantly, these results provide additional support for using our mRNA platform to potentially expedite the development of alternative approaches to traditional vaccines.”


    Key preclinical findings

    The main findings of the preclinical studies demonstrate the potential of MRT5500 to elicit neutralizing antibodies against SARS-CoV-2.


    In mice, four dose levels were assessed at 0.2, 1, 5 and 10 µg per dose using a two-dose vaccination schedule, administered three weeks apart. MRT5500 induced dose-dependent levels of binding antibodies and neutralizing antibodies specific to the SARS-CoV-2 spike protein. 100% seroconversion was observed at all dose levels after one administration, and a further increase in titers was observed following a second administration. Neutralizing antibody titers were observed across all dose levels after receiving the two-dose-administration regimen. In the higher dose groups (5 µg, 10 µg), titers were detected after one administration of MRT5500 and were more pronounced after the second administration.


    In non-human primates (NHPs), three dose levels were assessed at 15, 45 and 135 µg per dose using a two-administration vaccination schedule, three weeks apart. The potency of MRT5500 was assessed by two types of neutralization assays: pseudovirus neutralization and micro-neutralization. After the first administration, the majority of NHPs developed neutralizing antibodies reactive to the SARS-CoV-2 spike protein and those antibody titers were further enhanced after a second administration with 100% of NHPs reaching levels significantly higher than those from human convalescent sera by day 35.


    It was also demonstrated that MRT5500-immunized mice and non-human primates exhibited a Th1-biased T cell response against SARS-CoV-2.


    The preprint publication “Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and non-human primates,” is available here.


    Shots on goal in the fight against COVID-19

    In addition to the mRNA vaccine candidate in collaboration with Translate Bio, Sanofi is collaborating with GSK on a COVID-19 vaccine candidate using the same recombinant protein-based manufacturing technology as one of Sanofi’s seasonal influenza vaccines, combined with GSK’s established pandemic adjuvant platform. The Companies announced the start of the Phase 1/2 clinical trial for their adjuvanted recombinant COVID-19 vaccine candidate in September and anticipate first results in early December 2020, to support the initiation of a pivotal Phase 3 study before the end of the year.


    About mRNA vaccines

    Vaccines work by mimicking disease agents to stimulate the immune system, building up a defense mechanism that remains active in the body to fight future infections. mRNA vaccines offer an innovative approach by delivering a nucleotide sequence encoding the antigen or antigens selected for their high potential to induce a protective immune response. mRNA vaccines also represent a potentially innovative alternative to conventional vaccine approaches for several reasons - their high potency, ability to initiate protein production without the need for nuclear entry, capacity for rapid development and potential for low-cost manufacture and safe administration using non-viral delivery. This approach potentially enables the development of vaccines for disease areas where vaccination is not a viable option today. Additionally, a desired antigen or multiple antigens can be expressed from mRNA without the need to adjust the production process, offering maximum flexibility and efficiency in development.


    About the Sanofi Pasteur and Translate Bio collaboration

    In 2018, Translate Bio entered into a collaboration and exclusive license agreement with Sanofi Pasteur Inc., the vaccines global business unit of Sanofi, to develop mRNA vaccines for up to five infectious disease pathogens. The agreement was first expanded in March 2020 to include development of a novel mRNA vaccine for COVID-19. In June 2020, the two Companies built upon the existing collaboration to pursue novel mRNA vaccines to broadly address current and future infectious diseases.


    This collaboration brings together Sanofi Pasteur’s leadership in vaccines and Translate Bio’s mRNA research and development expertise. Under the agreement, the Companies are jointly conducting research and development activities to advance mRNA vaccines and mRNA vaccine platform development during a research term of at least four years after the original signing in 2018.


    About Translate Bio

    Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease. Translate Bio’s lead pulmonary candidate is being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio believes that mRNA can be delivered to target tissues via multiple routes of administration and, consequently, its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.



    About Sanofi



    Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.



    With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.



    Sanofi, Empowering Life



    Sanofi Media Relations

    Nicolas Kressmann

    Tel.: +1 (732) 532 53-18

    [email protected]





    Translate Bio Media Relations

    Maura Gavaghan

    Tel: +1 (617) 233-1154


    [email protected]


    Sanofi Investor Relations - Paris

    Eva Schaefer-Jansen

    Arnaud Delepine

    Yvonne Naughton



    Sanofi Investor Relations – North America

    Felix Lauscher

    Fara Berkowitz

    Suzanne Greco



    IR Main Line:

    Tel.: +33 (0)1 53 77 45 45

    [email protected]





    Translate Bio Investor Relations

    Teri Dahlman

    Tel: +1 (617) 817-8655


    [email protected]



    Sanofi Forward-Looking Statements

    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly, and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2019. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

  • lab leak


    External Content youtu.be
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • Origin of Covid — Following the Clues

    Did people or nature open Pandora’s box at Wuhan?

    Nicholas Wade

    40 minute read



    https://nicholaswade.medium.co…ing-the-clues-6f03564c038



    The Covid-19 pandemic has disrupted lives the world over for more than a year. Its death toll will soon reach three million people. Yet the origin of pandemic remains uncertain: the political agendas of governments and scientists have generated thick clouds of obfuscation, which the mainstream press seems helpless to dispel.

    In what follows I will sort through the available scientific facts, which hold many clues as to what happened, and provide readers with the evidence to make their own judgments. I will then try to assess the complex issue of blame, which starts with, but extends far beyond, the government of China.

    By the end of this article, you may have learned a lot about the molecular biology of viruses. I will try to keep this process as painless as possible. But the science cannot be avoided because for now, and probably for a long time hence, it offers the only sure thread through the maze.

    The virus that caused the pandemic is known officially as SARS-CoV-2, but can be called SARS2 for short. As many people know, there are two main theories about its origin. One is that it jumped naturally from wildlife to people. The other is that the virus was under study in a lab, from which it escaped. It matters a great deal which is the case if we hope to prevent a second such occurrence.

    I’ll describe the two theories, explain why each is plausible, and then ask which provides the better explanation of the available facts. It’s important to note that so far there is no direct evidence for either theory. Each depends on a set of reasonable conjectures but so far lacks proof. So I have only clues, not conclusions, to offer. But those clues point in a specific direction. And having inferred that direction, I’m going to delineate some of the strands in this tangled skein of disaster.

    A Tale of Two Theories

    After the pandemic first broke out in December 2019, Chinese authorities reported that many cases had occurred in the wet market — a place selling wild animals for meat — in Wuhan. This reminded experts of the SARS1 epidemic of 2002 in which a bat virus had spread first to civets, an animal sold in wet markets, and from civets to people. A similar bat virus caused a second epidemic, known as MERS, in 2012. This time the intermediary host animal was camels.

    The decoding of the virus’s genome showed it belonged a viral family known as beta-coronaviruses, to which the SARS1 and MERS viruses also belong. The relationship supported the idea that, like them, it was a natural virus that had managed to jump from bats, via another animal host, to people. The wet market connection, the only other point of similarity with the SARS1 and MERS epidemics, was soon broken: Chinese researchers found earlier cases in Wuhan with no link to the wet market. But that seemed not to matter when so much further evidence in support of natural emergence was expected shortly.

    Wuhan, however, is home of the Wuhan Institute of Virology, a leading world center for research on coronaviruses. So the possibility that the SARS2 virus had escaped from the lab could not be ruled out. Two reasonable scenarios of origin were on the table.

    From early on, public and media perceptions were shaped in favor of the natural emergence scenario by strong statements from two scientific groups. These statements were not at first examined as critically as they should have been.

    “We stand together to strongly condemn conspiracy theories suggesting that COVID-19 does not have a natural origin,” a group of virologists and others wrote in the Lancet on February 19, 2020, when it was really far too soon for anyone to be sure what had happened. Scientists “overwhelmingly conclude that this coronavirus originated in wildlife,” they said, with a stirring rallying call for readers to stand with Chinese colleagues on the frontline of fighting the disease.

    Contrary to the letter writers’ assertion, the idea that the virus might have escaped from a lab invoked accident, not conspiracy. It surely needed to be explored, not rejected out of hand. A defining mark of good scientists is that they go to great pains to distinguish between what they know and what they don’t know. By this criterion, the signatories of the Lancet letter were behaving as poor scientists: they were assuring the public of facts they could not know for sure were true.

    It later turned out that the Lancet letter had been organized and drafted by Peter Daszak, president of the EcoHealth Alliance of New York. Dr. Daszak’s organization funded coronavirus research at the Wuhan Institute of Virology. If the SARS2 virus had indeed escaped from research he funded, Dr. Daszak would be potentially culpable. This acute conflict of interest was not declared to the Lancet’s readers. To the contrary, the letter concluded, “We declare no competing interests.”


  • Great Zorud you help your free mason friend JED with a friendly article with no scientific background just an interview that contains more lies than facts.


    All vaccines first must be tested on chimpanzees = human primates. Shows us these tests please - has been done for Ebola. Bad news not enough chimpanzees available for 20 new vaccines...Also very expensive.

  • Great Zorud you help your free mason friend JED with a friendly article with no scientific background just an interview that contains more lies than facts.


    All vaccines first must be tested on chimpanzees = human primates. Shows us these tests please - has been done for Ebola. Bad news not enough chimpanzees available for 20 new vaccines...Also very expensive.

    This from a previous post on the animal study for Pfizer-BioNTech


    Two animal models have been developed for Covid 19, mice and macaques (monkeys). Interesting, the Syrian hamster is stated to be the closest match to humans for Covid-19 testing. “The lungs of infected hamsters exhibit the pathological lesions analogous to the COVID-19 patients with pneumonia. Moreover, the nAb response exhibited by the infected hamster demonstrated immunity against the succeeding re-challenge studies. Furthermore, the transfusion of convalescent sera into the naïve hamsters mounted the antibody response and hence hindered the viral replication in the lungs.”**. I included this statement to emphasize the considerations involved in selecting the animals to use in the trials.

  • Estimated Spike Evolution and Impact of Emerging SARS-CoV-2 Variants


    https://www.medrxiv.org/conten…101/2021.05.06.21256705v1


    Abstract

    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, has been mutating and thus variants emerged. This suggests that SARS-CoV-2 could mutate at an unsteady pace. Supportive evidence comes from the accelerated evolution which was revealed by tracking mutation rates of the genomic location of Spike protein. This process is sponsored by a small portion of the virus population but not the largest viral clades. Moreover, it generally took one to six months for current variants that caused peaks of COVID-19 cases and deaths to survive selection pressure. Based on this statistic result and the above speedy Spike evolution, another upcoming peak would come around July 2021 and disastrously attack Africa, Asia, Europe, and North America. This is the prediction generated by a mathematical model on evolutionary spread. The reliability of this model and future trends out of it comes from the comprehensive consideration of factors mainly including mutation rate, selection course, and spreading speed. Notably, if the prophecy is true, then the new wave will be the first determined by accelerated Spike evolution.

  • Interesting, the Syrian hamster is stated to be the closest match to humans for Covid-19 testing.

    These kind - functional effect verification - of animal tests are always done. But the safety tests have a long duration and cost tons of money. So no current vaccine in use for CoV-19 so far did it.

    Or simply said: If you take a CoV-19 vaccine you are the test monkey.

  • Sad

    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • Israel’s promising ‘precision’ COVID drug starting trial in Greece next week

    Medicine hailed as a ‘huge breakthrough’ by inventors and as a ‘miracle drug’ by Netanyahu embarks on path to possible approval, in hope it will help crisis spots like India


    https://www.timesofisrael.com/…rial-in-greece-next-week/


    Israel’s “precision medicine” for COVID-19, which tackles the immune overreaction that causes deterioration from the disease, will start a second round of clinical trials in Greece next week.


    The testing comes with interest in coronavirus drugs sky-high, amid spiraling cases in several countries where widespread vaccine protection isn’t expected anytime soon, including India, where there are more than 300,000 new cases per day, and Nepal, where hospitals are struggling

    The inhaled drug EXO-CD24 was given to 30 patients in moderate condition or worse, and all of them recovered, 29 of them within three to five days. In February Tel Aviv’s Ichilov Medical Center revealed that it had invented and started testing the drug, calling it a “huge breakthrough.” It has since been subjected to further testing in vitro and on animals in Israel, and has performed well.


    Another small human trial is planned for Israel but the main trials are moving to Greece, as Israel has few hospitalized coronavirus patients following its successful vaccination campaign.

    Now we will start Phase 2 testing, and it’s important to advance this drug as there are countries that don’t yet have vaccines,” said the drug’s inventor, Prof. Nadir Arber, a senior doctor at Ichilov. “We still need drugs like ours, which can be produced rapidly, efficiently and cheaply.”

    Explaining how the drug works, he said: “It inhibits the cytokine storm, which is the overstimulation of the immune system, intervening precisely at the place where the ‘fire’ is. It’s precision medicine.”


    In February, on the same day that Prime Minister Benjamin Netanyahu met with Arber and asked him about his “miracle drug,” the premier lauded the drug to visiting Greek Prime Minister Kyriakos Mitsotakis, who suggested that a Greek hospital run a clinical trial.


    Arber told The Times of Israel on Thursday that the Phase 2 trial in Greece will involve 90 coronavirus patients.

    It will compare two different doses to see which will be most effective,” he said. “Then, in a further study in Greece, we will be comparing between placebo and the chosen dose of the drug.”


    He said that the Phase 2 trial will take around two months, and if all goes according to plan, the drug could be available for widespread use in hospitals by the end of 2021.

  • I can't explain India just hope the downward tread continues. Now as for the vaccine you skipped my post from the WHO, the Efficacy of the vaccine mirrors oxford and I&j vaccines. And is working just fine, or is the WHO lying?

  • Shocking WHO report says COVID-19 pandemic was preventable

    WHO knows what should have been done.


    https://thehill.com/changing-a…covid-19-pandemic-was?amp


    An independent panel said the COVID-19 pandemic was avoidable if world leaders acted appropriately, The Hill reported.


    Former New Zealand prime minister Helen Clark and Ellen Johnson Sirleaf, a former president of Liberia, were part of a panel called the Independent Panel for Pandemic Preparedness and Response, and they have criticized global leaders and demanded better actions in the future

    The Independent Panel for Pandemic Preparedness and Response (IPPPR) is a team of experts assembled by the World Health Organization Director-General Tedros Adhanom Ghebreyesus last May to examine the pandemic.


    The review from IPPR stated that efforts to stop the spread were inconsistent and underfunded. The report also chastises the alert system for being slow and subdued.


    "[February 2020] is a month of lost opportunity to avert a pandemic, as so many countries chose to wait and see," Clark said.


    "For some, it wasn't until hospital ICU beds began to fill that more action was taken," she said. "And by then it was too late to avert the pandemic impact. What followed then was a winner takes all scramble for PPE and therapeutics. Globally, health workers were tested to their limits and the rates of infection, illness and death soared and continue to soar."


    "The situation we find ourselves in today could have been prevented. An outbreak of a new pathogen, Sars CoV-2 became a catastrophic pandemic that has now killed more than 3.25 million people, and continues to threaten lives and livelihoods all over the world," Sirleaf said. "It is due to a myriad of failures, gaps and delays in preparedness and response. This was partly due to failure to learn from the past."


    The panel urges world leaders to donate at least 1 billion vaccine doses to low- and middle-income countries as part of WHO's Covax Gavi Advance Market Commitment, a vaccine equity plan to ensure more than 2 billion doses get provided by mid-2022, Market Watch reported.

  • Autoimmune activation after vaccination?


    Blood Expert Says He Found Why Some Covid-19 Vaccines Trigger Rare Clots

    A scientist in Germany thinks he has found an answer as researchers around world examine AstraZeneca and Johnson & Johnson shots


    https://www.wsj.com/amp/articl…e-blood-clots-11620898201


    Scientists world-wide are racing to understand why Covid-19 vaccines from AstraZeneca PLC and Johnson & Johnson are causing rare but potentially deadly blood clots.


    Determining the connection would help patients, doctors and health agencies better assess any risks posed by the vaccines and safely calibrate their use. In recent weeks, the U.S., the Canadian province of Ontario and several European countries including Norway and Denmark either paused or completely halted rollouts involving these vaccines.


    “Understanding the cause is of highest importance for the next-generation vaccines, because [the novel] coronavirus will stay with us and vaccination will likely become seasonal,” said Eric van Gorp, a professor at Erasmus University in the Netherlands who heads a group of scientists studying the condition.

    In Germany, one researcher thinks he has found what is triggering the clots. Andreas Greinacher, a blood expert, and his team at the University of Greifswald believe so-called viral vector vaccines—which use modified harmless cold viruses, known as adenoviruses, to convey genetic material into vaccine recipients to fight the coronavirus—could cause an autoimmune response that leads to blood clots. According to Prof. Greinacher, that reaction could be tied to stray proteins and a preservative he has found in the AstraZeneca vaccine.


    Prof. Greinacher and his team has just begun examining Johnson & Johnson’s vaccine but has identified more than 1,000 proteins in AstraZeneca’s vaccine derived from human cells, as well as a preservative known as ethylenediaminetetraacetic acid, or EDTA. Their hypothesis is that EDTA, which is common to drugs and other products, helps those proteins stray into the bloodstream, where they bind to a blood component called platelet factor 4, or PF4, forming complexes that activate the production of antibodies.

    The inflammation caused by the vaccines, combined with the PF4 complexes, could trick the immune system into believing the body had been infected by bacteria, triggering an archaic defense mechanism that then runs out of control and causes clotting and bleeding.

    Prof. Greinacher has compared the activation of the dormant response—which has been supplanted in the evolution of the human immune system, but still lurks in its foundations—to “awakening a sleeping dragon.”


    Prof. John Kelton of McMaster University in Canada, whose outfit runs Canada’s reference lab for testing patients with blood-clotting symptoms after vaccination, said the lab replicated some of Prof. Greinacher’s research and confirmed his findings.


    Yet the cause was unclear. “[Prof. Greinacher’s] hypothesis could be right, but it could also be wrong,” Prof. Kelton said.

    Prof. Greinacher is working to confirm his theory, hoping to get cooperation from vaccine makers. His team has tested AstraZeneca vaccines and has just received doses from Johnson & Johnson. Greifswald University is now negotiating with the drugmakers about greater access to their vaccine-making processes.


    “We strongly support raising awareness of the signs and symptoms of this very rare event, and we are currently exploring a potential collaboration with Dr. Greinacher,” said a Johnson & Johnson spokesman.


    AstraZeneca didn’t respond to a request for comment.

    The type of clotting observed is known as vaccine-induced immune thrombotic thrombocytopenia, or VITT. Peer-reviewed studies by Prof. Greinacher’s group, as well as from teams at the University of Oslo and University College London have independently confirmed its existence.

    Most of the science hubs investigating the clotting issue, first identified in March, are experts in a condition called heparin-induced thrombocytopenia or HIT, which has near-identical symptoms and outcomes to VITT. With HIT, the blood-thinning drug heparin causes clots paired with an abnormal decrease in the blood’s natural clotting agents.


    Some scientists think the adenoviruses themselves could play a role in triggering the condition because they have been linked to blood clotting. Others speculate that people affected could have genetic predispositions, or that their immune systems had previously developed the problematic antibody.


    Another theory suggested by Prof. van Gorp is that the brief but strong flulike symptoms many recipients report after taking the shot are also causing inflammation that could trigger or exacerbate autoimmune reactions leading to blood clotting.

    One reason vaccine-induced clotting might not have been reported in the past is because shots using viral vector technology haven’t been administered at scale. The Russian vaccine Sputnik V and the shot by CanSino Biologics from China use the same technology as AstraZeneca and Johnson & Johnson, but haven’t been linked to the condition so far.

    The only similar shot widely administered before the pandemic is one against Ebola by Johnson & Johnson, which was given to at least 60,000 people as of last July.


    Clotting occurs between one in 28,000 and one in 100,000, according to European data—extremely rare amid the hundreds of millions of doses administered so far, yet higher than one in 150,000 previously assumed by some medical authorities, Prof. Greinacher said. Most of the hundreds of people who have been diagnosed recover, but between a fifth and a third have died, and others could suffer permanent consequences.


    Data from U.S. and European regulators so far suggest young women are primarily affected by the condition. But several scientists, including Sabine Eichinger, a senior Austrian hematologist who treated one of the first-known patients, have said the correlation could reflect that medical workers and teachers were among the first to get the vaccines in Europe, and the majority of them are younger women.

    There is no indication that taking contraception pills or having a history of similar diseases puts vaccine recipients at greater risk, Prof. Eichinger said.


    Anton Pottegård, a professor of pharmacoepidemiology at the University of Southern Denmark, co-wrote a study of more than 280,000 people in Denmark and Norway who received the AstraZeneca vaccine. The study, which was published in the British Medical Journal on May 5, found the incidence of rare but severe blood clots among vaccine recipients was 2.5 in 100,000.


    Prof. Pottegård added that countries such as Denmark and Norway, which this week discontinued using AstraZeneca’s vaccine and donated its doses to other countries, were able to change their inoculation plans because they had alternative shots and low infection rates. Doing the same in countries where the pandemic is raging, such as India or Brazil, could result in more deaths, he warned.


    “Covid-19 is much, much, much more dangerous than this extremely rare condition,” Prof. Greinacher said.

  • https://covid19criticalcare.co…paign-against-ivermectin/srael’s promising ‘precision’ COVID drug starting trial in Greece next week

    Medicine hailed as a ‘huge breakthrough’ by inventors and as a ‘miracle drug’ by Netanyahu embarks on path to possible approval, in hope it will help crisis spots like India

    Guess with the right bribing they can convince WHO/FDA/CDC...

    Else the following thing happens: https://covid19criticalcare.co…paign-against-ivermectin/

    Their hypothesis is that EDTA, which is common to drugs and other products, helps those proteins stray into the bloodstream, where they bind to a blood component called platelet factor 4, or PF4, forming complexes that activate the production of antibodies.

    This is one reason why I Prefer J&J... But we still have the "heparin" induced cloths that are a genetical issue.


    see:

    Most of the science hubs investigating the clotting issue, first identified in March, are experts in a condition called heparin-induced thrombocytopenia or HIT, which has near-identical symptoms and outcomes to VITT. With HIT, the blood-thinning drug heparin causes clots paired with an abnormal decrease in the blood’s natural clotting agents.

    And do not forget: WITH RNA vaccines there are 2..3x more cloths...

    I can't explain India just hope the downward tread continues.

    Goa went all in with Ivermectin Others might follow.


    The panel urges world leaders to donate at least 1 billion vaccine doses to low- and middle-income countries as part of WHO's Covax Gavi Advance Market Commitment


    This generates 20 billion income for big pharma + 60 Billion at least for doctors, vaccination site owners etc.. The same for Ivermectin would only result in 100 mio.

  • Covid hitting below the belt


    COVID-19 can infect penis tissue and could lead to erectile dysfunction - study

    A co-author of the study says this was "yet another reason that we should all do our best to avoid COVID-19".


    https://news.sky.com/story/amp…ysfunction-study-12304902


    COVID-19 can infect tissue in the penis and potentially contribute to erectile dysfunction, researchers have found.


    A scientific research paper published in the World Journal of Men's Health observed the difference in tissue composition between men who had contracted the disease and men who had not.


    COVID can cause damage to blood vessels, which in turn can damage parts of the body the vessels supply, including the sponge-like tissue in the penis.

    Ranjith Ramasamy, associate professor and director of the University of Miami Miller School of Medicine's reproductive urology programme, led the study.


    He said that erectile dysfunction "could be an adverse effect of the virus

    The study focused on four men who were having penile prosthesis surgery for erectile dysfunction.


    Two had suffered with COVID-19, and two had not. They were all aged between 65 and 71 and of Hispanic ethnicity.

    The pair who had the coronavirus were infected six and eight months before the observations, with one hospitalised for the virus and the other not.


    Neither had a history of erectile dysfunction.


    Remnants of the virus were observed in the penis tissue of the two COVID-positive men.

    The damage COVID causes to blood vessels is known as endothelial dysfunction.


    Dr Ramasamy said: "In our pilot study, we found that men who previously did not complain of ED [erectile dysfunction] developed pretty severe ED after the onset of COVID-19 infection."


    He added: "Our research shows that COVID-19 can cause widespread endothelial dysfunction in organ systems beyond the lungs and kidneys.


    "The underlying endothelial dysfunction that happens because of COVID-19 can enter the endothelial cells and affect many organs, including the penis."

    Eliyahu Kresch, a medical student working with Dr Ramasamy, said: "These latest findings are yet another reason that we should all do our best to avoid COVID-19."


    The paper suggested: "For now, history of COVID-19 should be included in the work-up of ED and positive findings should be investigated accordingly.


    "Patients should be aware of the potential complication of post-COVID-19 ED.

    Any changes observed in ED after infection should be followed up with the appropriate specialist for treatment and to help further investigation into the condition.


    "Future studies are needed to validate the effects of this virus on sexual function."

  • "The underlying endothelial dysfunction that happens because of COVID-19 can enter the endothelial cells and affect many organs, including the penis."

    Most tissues will recover if no inflammation starts. The question is how long this takes.

    Endothelia infection of eyes is much more severe. But happens also with other virus. Same as Diabetes I promotion.